An observational study in Osteogenesis Imperfecta and Short Stature, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Completed at 1 site in United States. Open to participants aged 1 Day to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Observational
Background:
Osteogenesis Imperfecta (OI) is a connective tissue disorder. OI affects many aspects of a person s health and growth. It can cause frequent fractures, short stature, and bowing of the long bones. There is no known cure for OI so researchers want to learn more about it.
Objectives:
To obtain a natural history of the course of OI. To find changes in genes that affect the disease.
Eligibility:
People from birth to age 12 years with certain types of OI
People who previously had childhood data collected in certain other protocols
Design:
Participants will stay in the clinic for a few days each visit. Visits will be about every 3-4 months to age 5 then about every 6-12 months. Visits may include:
Medical history
Physical exam
Hearing test
Dental exam
Blood, urine, and heart tests
Breathing measured while wearing a clear plastic hood for about 30 minutes
Tests of motion, strength, and motor skills
X-rays of the left hand, chest, legs, and spine
Bone density scan. Participants will lie on a flat table while a very small dose of x-rays is passed through the body.
Computed tomography and magnetic resonance imaging scans. Participants will lie on an exam table that moves in and out a scanner.
Breathing tests using stickers on the chest, a light probe on a finger or foot, and a face mask
Ultrasound of the kidneys, ureters, and bladder
Questionnaires
A small section of skin removed from the arm or thigh
For some tests, participants may take medicine to make them sleepy.
Participants may give separate consent for photos to be taken.
study Description:
This is a longitudinal study of the natural history of the collagen-related disorder osteogenesis imperfecta (OI), that includes enrolling new patients under the age of 12 years, along with an extended data collection from adult patients on whom previous childhood data was collected at the NIH.
Objectives:
Primary Objectives: 1) Identify and monitor longitudinal functional outcomes of individuals with collagen and collagen-related disorders, with focuses on identifying underlying contributing factors and comorbidities for scoliosis; gaining insight into occurrence and progression of cardiac valvular abnormalities; pathogenesis of primary lung parenchymal defects; and establish novel data relating to metabolism in OI and its relationship to obesity. 2) Correlate genotypic and phenotypic expression. 3) Identify genetic factors that modify the severity of clinical expression
Secondary Objectives: Adapt and develop standard of care management guidelines for individuals with collagen and collagen-related disorders.
Endpoints:
Primary Endpoints: 1) Clinical course, underlying pathogenesis, and comorbidities in the assessed systems in individuals with OI including for each focus: scoliosis progression across age, scoliosis progression relating to predictive factor, and scoliosis progression relating to mutation spectrum; time to development of valvular abnormality; development of pulmonary tissue abnormalities, presence/absence of pulmonary tissue abnormality, and time to development of pulmonary tissue abnormality; time to development of metabolic abnormality. 2) Correlation of phenotype relating to genotype. 3) Causes of morbidities in individuals with OI.
Secondary endpoints: Tolerability and feasibility of each measure of the clinical battery of assessments based on clinical observation.
84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
This study's enrollment of 46 is below the median of 75 across 23 observational studies indexed under Osteogenesis Imperfecta.
Browse Osteogenesis Imperfecta studies →Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the lead sponsor of 422 studies on the registry; 24 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individuals of all ages, races, genders, and nationalities@@@@@@
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet either #1 OR #2 of the following criteria:
Individuals previously enrolled in 97-CH-0064, or other NIH OI study protocols for whom childhood data were collected at the NIH.
OR
a diagnosis of any of OI type III - XVIII or potential additional types.
Diagnosis of OI determined by identification of:
A mutation in one allele of genes causing autosomal dominant OI types
(COL1A1, COL1A2, or IFITM5), OR
OR
Individuals with a clinical diagnosis of OI, and a mutation in one of the above genes identified through the Rare Bone disease screening protocol (04-CH-0077).
EXCLUSION CRITERIA:
\<TAB>
There are no exclusionary criteria related to race or gender for this protocol.
Individuals with Osteogenesis Imperfecta
Clinical course, underlying pathogenesis, and comorbidities in the assessed systems in individuals with OI
clinical course
Time frame: Ongoing
Correlation of genotype and phenotype
genotype-phenotype correlations
Time frame: Ongoing
Causes of morbidities in individuals with OI
clinical course
Time frame: Ongoing
Tolerability and feasibility of each measure of the clinical battery of assessments based on clinical observation
Time frame: Ongoing
Plan to share: Undecided — Once primary and secondary endpoints are met to be able to publish/share, we will create a plan to address the IPD sharing as well.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) →